Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 2,086 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Open Label Extension Study Clear all

Conditions: Lupus Nephritis
Interventions: Placebo plus standard therapy, Belimumab 10 mg/kg plus standard therapy, Standard therapy; Biological · Drug
Lead sponsor: Human Genome Sciences Inc., a GSK Company; Industry
Eligibility: 18 Years and older
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 17
States / cities: La Palma, California • San Leandro, California • Torrance, California + 13 more

Conditions: Sickle Cell Disease
Interventions: IMR-687; Drug
Lead sponsor: Imara, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 3
States / cities: Farmington, Connecticut • Hollywood, Florida • Temple, Texas

Conditions: Schizophrenia
Interventions: SEP-363856; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 13 Years to 65 Years
Enrollment: 463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 25
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 19 more

Conditions: Arthritis, Rheumatoid
Interventions: FKB327, Humira®; Drug
Lead sponsor: Fujifilm Kyowa Kirin Biologics Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 645 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 15
States / cities: Peoria, Arizona • Palm Desert, California • Boca Raton, Florida + 12 more

Conditions: Neoplasms
Interventions: RO5429083; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Houston, Texas • Seattle, Washington

Conditions: Leukocyte Adhesion Deficiency
Interventions: AVTX-803; Drug
Lead sponsor: AUG Therapeutics; Industry
Eligibility: 6 Months to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Osteoarthritis Knee
Interventions: Gel-One, PBS; Device
Lead sponsor: Seikagaku Corporation; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 814 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 41
States / cities: Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 38 more

Conditions: Lupus Erythematosus, Systemic
Interventions: Nipocalimab, Placebo, Standard of care treatment; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 40
States / cities: Beverly Hills, California • Hemet, California • La Palma, California + 35 more

Conditions: AL Amyloidosis
Interventions: NEOD001; Drug
Lead sponsor: Prothena Biosciences Ltd.; Industry
Eligibility: Not listed
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 5
States / cities: Stanford, California • Boston, Massachusetts • Detroit, Michigan + 2 more

Conditions: Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
Interventions: AP01; Combination Product
Lead sponsor: Avalyn Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 32
States / cities: Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 24 more

Conditions: Parkinson Disease
Interventions: Placebo, Pramipexole; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 30 Years and older
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 10
States / cities: Sun City, Arizona • Tempe, Arizona • La Jolla, California + 7 more

Conditions: Dermatomyositis, Polymyositis
Interventions: Dazukibart; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 4
States / cities: Glendale, Arizona • Frisco, Texas • Houston, Texas + 1 more

Conditions: Stroke, Chronic Stroke, Upper Extremity Paresis, Ischemic Stroke, Hemorrhagic Stroke
Interventions: Active Vagus Nerve Stimulation, Placebo Vagus Nerve Stimulation; Device
Lead sponsor: Baylor Research Institute; Other
Eligibility: 22 Years to 79 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Advanced Parkinson's Disease
Interventions: Levodopa-Carbidopa Intestinal Gel (LCIG), CADD-Legacy® 1400 ambulatory infusion pump, Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J); Drug · Device
Lead sponsor: AbbVie; Industry
Eligibility: 30 Years to 99 Years
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2021
U.S. locations: 31
States / cities: Birmingham, Alabama • Encinitas, California • Fountain Valley, California + 25 more

Conditions: Uremic Pruritus
Interventions: CR845 0.5 mcg/kg, Placebo; Drug
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 473 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 29
States / cities: Chula Vista, California • Fountain Valley, California • Northridge, California + 25 more

Conditions: Healthy Volunteers
Interventions: Apremilast IR, Apremilast XL; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 2
States / cities: Daytona Beach, Florida • Madison, Wisconsin

Conditions: X-Linked Hypophosphatemia
Interventions: burosumab, Oral Phosphate Supplement, active vitamin D; Biological · Drug
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 1 Year to 12 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 5
States / cities: Los Angeles, California • San Francisco, California • Indianapolis, Indiana + 2 more

Conditions: Hematologic Malignancy, Solid Tumor, Advanced Malignancies
Interventions: Pelabresib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Los Angeles, California • Jacksonville, Florida • Chicago, Illinois + 2 more

Conditions: Generalized Myasthenia Gravis
Interventions: ALXN1720, Placebo; Combination Product
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 23
States / cities: Orange, California • Fort Collins, Colorado • Washington D.C., District of Columbia + 20 more

Conditions: Frontotemporal Dementia
Interventions: DNL593, Placebo; Drug
Lead sponsor: Denali Therapeutics Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 3
States / cities: San Francisco, California • Baltimore, Maryland • Philadelphia, Pennsylvania

Conditions: Agitation, Dementia
Interventions: T2:C100, Placebo; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 40 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 10
States / cities: Washington D.C., District of Columbia • Miami, Florida • Tampa, Florida + 6 more

Conditions: Alzheimer's Disease
Interventions: AC-1204, Placebo; Drug
Lead sponsor: Cerecin; Industry
Eligibility: 66 Years to 90 Years
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 82
States / cities: Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 69 more

Conditions: Migraine
Interventions: Rimegepant, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 636 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 27
States / cities: Phoenix, Arizona • Long Beach, California • Aurora, Colorado + 18 more

Conditions: Solid Tumor, Hematological Malignancies
Interventions: Belinostat, Atazanavir; Drug
Lead sponsor: Acrotech Biopharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Santa Monica, California

Search by objective public record fields.

Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis

An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia

A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia

A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients

A Study of RO5429083 in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors

An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects With Leukocyte Adhesion Deficiency Type II

Gel-One Treatment in Knee Osteoarthritis

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).

A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies

Wireless Nerve Stimulation Device To Enhance Recovery After Stroke

Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease

CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

A Study to Evaluate the Pharmacokinetic Exposure of 2 Formulations of Apremilast in Healthy Adults

Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)

Life's End Benefits of cannaBidiol and tetrahYdrocannabinol

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials